Inventiva Announces The Data Monitoring Committee Recommended To Continue The Clinical Trial Without Modification Of The Current Protocol, Based On The Pre-planned Review Of Safety Data

BenzingaOct 30 16:05 ET

Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH

BenzingaOct 30 16:01 ET

Express News | Inventiva Announces Abstract From LEGEND, Phase 2 Trial, Evaluating Lanifibranor In Combination With Empagliflozin In Mash At The Aasld The Liver Meeting 2024

BenzingaOct 21 08:40 ET

Top Premarket Decliners

MT NewswiresOct 16 07:58 ET

Inventiva's 2024 Interim Financial Highlights and Prospects

TipRanksOct 15 16:27 ET

6-K: Report of foreign private issuer (related to financial reporting)

SECOct 15 16:15 ET · Announcements